130 related articles for article (PubMed ID: 38417290)
1. Androgen receptor cofactors: A potential role in understanding prostate cancer.
Li X; Xiong H; Mou X; Huang C; Thomas ER; Yu W; Jiang Y; Chen Y
Biomed Pharmacother; 2024 Apr; 173():116338. PubMed ID: 38417290
[TBL] [Abstract][Full Text] [Related]
2. In vitro gene expression changes of androgen receptor coactivators after hormone deprivation in an androgen-dependent prostate cancer cell line.
Chang HC; Chen SC; Chen J; Hsieh JT
J Formos Med Assoc; 2005 Sep; 104(9):652-8. PubMed ID: 16276440
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer.
Shiota M; Yokomizo A; Fujimoto N; Naito S
Curr Cancer Drug Targets; 2011 Sep; 11(7):870-81. PubMed ID: 21762076
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells.
Heemers HV; Schmidt LJ; Kidd E; Raclaw KA; Regan KM; Tindall DJ
Prostate; 2010 Jun; 70(9):959-70. PubMed ID: 20166126
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer.
Li P; Yu X; Ge K; Melamed J; Roeder RG; Wang Z
Am J Pathol; 2002 Oct; 161(4):1467-74. PubMed ID: 12368219
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
Cai Z; Chen W; Zhang J; Li H
Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
8. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
[TBL] [Abstract][Full Text] [Related]
9. Expression of androgen receptor coregulators in prostate cancer.
Linja MJ; Porkka KP; Kang Z; Savinainen KJ; Jänne OA; Tammela TL; Vessella RL; Palvimo JJ; Visakorpi T
Clin Cancer Res; 2004 Feb; 10(3):1032-40. PubMed ID: 14871982
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol Triggers Nuclear Co-Association of Androgen Receptor, p160 Steroid Coactivators, and p300/CBP-Associated Factor Leading to Androgenic Axis Transactivation in Castration-Resistant Prostate Cancer.
Pimenta R; Camargo JA; Candido P; Ghazarian V; Gonçalves GL; Guimarães VR; Romão P; Chiovatto C; Mioshi CM; Dos Santos GA; Silva IA; Birbrair A; Srougi M; Nahas WC; Leite KR; Viana NI; Reis ST
Cell Physiol Biochem; 2022 Dec; 56(S4):1-15. PubMed ID: 36458578
[TBL] [Abstract][Full Text] [Related]
11. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.
Han D; Gao S; Valencia K; Owiredu J; Han W; de Waal E; Macoska JA; Cai C
Oncotarget; 2017 Jan; 8(4):6796-6808. PubMed ID: 28036278
[TBL] [Abstract][Full Text] [Related]
12. PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.
Puhr M; Hoefer J; Eigentler A; Dietrich D; van Leenders G; Uhl B; Hoogland M; Handle F; Schlick B; Neuwirt H; Sailer V; Kristiansen G; Klocker H; Culig Z
Oncogene; 2016 May; 35(18):2322-32. PubMed ID: 26257066
[TBL] [Abstract][Full Text] [Related]
13. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer.
Yeh S; Sampson ER; Lee DK; Kim E; Hsu CL; Chen YL; Chang HC; Altuwaijri S; Huang KE; Chang C
J Formos Med Assoc; 2000 Dec; 99(12):885-94. PubMed ID: 11155740
[TBL] [Abstract][Full Text] [Related]
15. Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer.
Perner S; Cronauer MV; Schrader AJ; Klocker H; Culig Z; Baniahmad A
Oncotarget; 2015 Nov; 6(34):35542-55. PubMed ID: 26325261
[TBL] [Abstract][Full Text] [Related]
16. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.
Chattopadhyay I; Wang J; Qin M; Gao L; Holtz R; Vessella RL; Leach RW; Gelman IH
Oncotarget; 2017 Feb; 8(6):10324-10347. PubMed ID: 28055971
[TBL] [Abstract][Full Text] [Related]
17. Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.
Denmeade SR; Sena LA; Wang H; Antonarakis ES; Markowski MC
Oncologist; 2023 Jun; 28(6):465-473. PubMed ID: 37027449
[TBL] [Abstract][Full Text] [Related]
18. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.
Yang YC; Banuelos CA; Mawji NR; Wang J; Kato M; Haile S; McEwan IJ; Plymate S; Sadar MD
Clin Cancer Res; 2016 Sep; 22(17):4466-77. PubMed ID: 27140928
[TBL] [Abstract][Full Text] [Related]
19. miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells.
Gong AY; Eischeid AN; Xiao J; Zhao J; Chen D; Wang ZY; Young CY; Chen XM
BMC Cancer; 2012 Oct; 12():492. PubMed ID: 23095762
[TBL] [Abstract][Full Text] [Related]
20. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
